Updated time: 2022-07-04 10:20:26
12A-1060929
PCT、TW I768182
For detecting the expression of PSPC1 Y523 residue in patients, the antibody for detecting nucleus expression of PSPC1 Y523 in IHC could be developed for pathological usage for biomarker compared to normal and tumor tissues. Enforcement of our discovery, clinical doctor can identify the specific patients within PSPC1 overexpression patients and choose PSPC1 Y523 monoclonal antibody for treatment of late-stage HCC patients. Besides, the TCGA public dataset showed that amplified-PSPC1 is a significant unfavorable marker in HCC patients, suggesting PSPC1 Y523 monoclonal antibody may also therapeutic effect to those patients.
- Our study indicates that Y523 residue site of PSPC1 by PTK6 phosphorylation may serve as a prognosis biomarker in HCC metastasis.
- Our findings provide a concept that patients with lower expression of PSPC1 Y523 tumor tissues have a potential to treat P21d inhibitor, suggesting that PSPC1 Y523 residue have a potential to develop into a monoclonal antibody for new therapeutic agents in late stage of HCC patients clinically.
The present invention relates generally to anti-cancer therapy, more specifically to treatment of PSPC1 nuclear-expressing cancer cells in divergent cancer types.
Yuh-Shan Jou
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Phosphorylation of Y523 residue of PSPC1 is a biomarker for cancer progression and therapeutic intervention